medigraphic.com
ISSN 1029-3043 (Electronic)

2014, Number 4

<< Back Next >>

Medicentro 2014; 18 (4)

Acral lentiginous melanoma: a case report

Rodríguez MJR, Ibáńez CE, Vázquez EU

Language: Spanish
References: 9
Page: 189-192
PDF size: 128.43 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Slingluff CI Jr, Flaherty K, Rosenberg SA. Cutaneous melanoma. En: De Vita VT Jr, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011. p. 1643-91.

  2. American Cancer Society. Cancer Facts & Figures 2012 [internet]. Atlanta, Ga: American Cancer Society; 2012 [citado 17 abr. 2013]. Disponible en: http://www.google.com.cu/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0CDMQFjAC&u rl=http%3A%2F%2Fpressroom.cancer.org%2Fdownload%2F2012%2BCancer%2BFacts%2B% 2526%2BFigures.pdf&ei=MK4QVK2lCdW5ggT3g4HQDA&usg=AFQjCNHo1_zhIlAdehbjPfrR12 EZAPh22A&bvm=bv.74649129,d.eXYpressroom.cancer.org/download/2012+Cancer+Facts+% 26+Figures.pdf

  3. Hollestein LM, van den Akker SA, Nijsten T. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol. 2012;23(2): 524-30.

  4. Green AC, Williams GM, Logan V. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257-63.

  5. Schoenewolf NL, Bull C, Belloni B. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer. 2012;48:1842-52.

  6. Dummer R, Guggenheim M, Arnold AW. Updated Swiss guidelines for the treatment and followup of cutaneous melanoma. Swiss Med Wkly. 2011 Dec. 15;141: w13320.

  7. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011;24(5):879-97.

  8. Ascierto PA, Berking C, Agarwala SS, Schadendorf D, Van Herpen C, Queirolo P, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol [internet]. 2012 [citado 13 dic. 2013];30 (Suppl.; Abstr. 8511):[aprox. 1 p.]. Disponible en: http://meetinglibrary.asco.org/content/93855-114

  9. Edge SB, Byrd DR, Compton CC. Melanoma of the skin. En: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010. p. 325-44.




2020     |     www.medigraphic.com